Literature DB >> 14959788

Aerosol treatment of cystic fibrosis.

Lucila Garcia-Contreras1, Anthony J Hickey.   

Abstract

Different aerosol therapies have been employed to treat the underlying cause and symptoms of cystic fibrosis (CF) during the past two decades. A summary of the main elements of the disease and aerosol treatments employed in clinical care and experimental trials are presented. Methods of aerosol generation and characterization are reviewed. Suggestions for improving the current treatments are provided.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14959788     DOI： 10.1615/critrevtherdrugcarriersyst.v20.i5.10

Source DB:  PubMed          Journal:  Crit Rev Ther Drug Carrier Syst        ISSN： 0743-4863            Impact factor:   4.889


  12 in total

1.  Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier.

Authors:  Ying-Ying Wang; Samuel K Lai; Jung Soo Suk; Amanda Pace; Richard Cone; Justin Hanes
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

2.  Aztreonam lysine for inhalation solution in cystic fibrosis: profile report.

Authors:  Greg L Plosker
Journal:  Paediatr Drugs       Date:  2011-04-01       Impact factor: 3.022

3.  A nonhuman primate toxicology and immunogenicity study evaluating aerosol delivery of AERAS-402/Ad35 vaccine: Evidence for transient t cell responses in peripheral blood and robust sustained responses in the lungs.

Authors:  David A Hokey; Robert Wachholder; Patricia A Darrah; Diane L Bolton; Dan H Barouch; Krystal Hill; Veerabadran Dheenadhayalan; Stephan Schwander; C Steven Godin; Macaya Douoguih; Maria Grazia Pau; Robert A Seder; Mario Roederer; Jerald C Sadoff; Donata Sizemore
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 4.  Aztreonam lysine for inhalation solution: in cystic fibrosis.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2010-10-01       Impact factor: 9.546

5.  Synthesis and characterization of core∕shell Fe(3)O(4)∕ZnSe fluorescent magnetic nanoparticles.

Authors:  José M Vargas; Amber A McBride; John B Plumley; Yann Fichou; Tosifa A Memon; Vichiksha Shah; Nathaniel C Cook; Brian A Akins; Antonio C Rivera; Gennady A Smolyakov; James R O'Brien; Natalie L Adolphi; Hugh D C Smyth; Marek Osiński
Journal:  J Appl Phys       Date:  2011-04-08       Impact factor: 2.546

6.  Highly compacted DNA nanoparticles with low MW PEG coatings: in vitro, ex vivo and in vivo evaluation.

Authors:  Nicholas J Boylan; Jung Soo Suk; Samuel K Lai; Raz Jelinek; Michael P Boyle; Mark J Cooper; Justin Hanes
Journal:  J Control Release       Date:  2011-08-31       Impact factor: 9.776

7.  Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine.

Authors:  Jung Soo Suk; Samuel K Lai; Nicholas J Boylan; Michelle R Dawson; Michael P Boyle; Justin Hanes
Journal:  Nanomedicine (Lond)       Date:  2011-02       Impact factor: 5.307

8.  The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles.

Authors:  Jung Soo Suk; Samuel K Lai; Ying-Ying Wang; Laura M Ensign; Pamela L Zeitlin; Michael P Boyle; Justin Hanes
Journal:  Biomaterials       Date:  2009-01-26       Impact factor: 12.479

9.  Enhanced efficacy of local etoposide delivery by poly(ether-anhydride) particles against small cell lung cancer in vivo.

Authors:  Benjamin C Tang; Jie Fu; D Neil Watkins; Justin Hanes
Journal:  Biomaterials       Date:  2009-09-30       Impact factor: 12.479

Review 10.  Pharmaceutical aerosols for the treatment and prevention of tuberculosis.

Authors:  Shumaila N M Hanif; Lucila Garcia-Contreras
Journal:  Front Cell Infect Microbiol       Date:  2012-09-07       Impact factor: 5.293
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.